Systemic lupus erythematosus (SLE) is a relatively common systemic own immune rheumatic diseases, extensive clinical performance, multi-organ system involvement

Immune clinical manifestations are extensive, and multiple organ systems are affected

The risk of malignant tumors in SLE has become an increasingly serious problem, because the accumulation of immunosuppressive drugs may be associated with an increased risk of cancer

Because the accumulated immunosuppressive drugs may be multiple sites, the international cohort, lymphoma, leukemia, lung cancer, breast cancer, ovarian cancer, comprehensive meta-analysis

This study eventually covered 17,854 SLE patients in the NHIS database, most of them were females, accounting for 90.

The baseline characteristics of patients with systemic lupus erythematosus and the general population are shown in Table 1

1.

Crude IR of malignant tumors in SLE patients and the general population

During the observation period (60511 PYs), 836 cases (IR 138.

During the observation period (60511 PYs), 836 cases (IR 138.

2.

This study found that systemic lupus erythematosus is associated with an increased risk of solid malignancies (SIR 1.

Colon cancer

In terms of hematological malignancies, patients with SLE have a relatively high risk of multiple myeloma (SIR 8.

(Figure 2)

3.

There are certain differences in the risk of malignant tumors between women and men with SLE

There are certain differences in the risk of malignant tumors between women and men with SLE

Compared with the general population, the SIR of hematological malignancies in female SLE patients is: multiple myeloma (SIR 8.

In male patients with SLE, compared with the general population, NHL's SIR (SIR 12.
71, 95% CI 4.
41-21.
02) increased, but the risk of other hematological malignancies, such as leukemia (SIR 7.
80, 95% CI 0.
16-15.
45) And the risk of multiple myeloma (SIR 3.
90, 95% CI 0-11.
53) did not increase significantly
.
Although male SLE patients have an increased overall risk of solid malignancies (SIR 1.
78, 95% CI 1.
39–2.
16), compared with the general population, the risk of site-specific solid cancer does not increase (Table 3)
.

In male patients with SLE, compared with the general population, NHL's SIR (SIR 12.
71, 95% CI 4.
41-21.
02) increased, but the risk of other hematological malignancies, such as leukemia (SIR 7.
80, 95% CI 0.
16-15.
45) And the risk of multiple myeloma (SIR 3.
90, 95% CI 0-11.
53) did not increase significantly
.
Although male SLE patients have an increased overall risk of solid malignancies (SIR 1.
78, 95% CI 1.
39–2.
16), compared with the general population, the risk of site-specific solid cancer does not increase (Table 3)
.
(Table 3)
.

In summary, this study included 17,854 SLE patients.
During the observation period (60,511 person-years [PYs]), 768 solid malignancies (126.
9 / 10,000 PYs) and 68 hematological malignancies occurred in SLE patients.
(11.
2 / 10,000 PYs)
.
In SLE patients, breast cancer, reproductive system cancer and thyroid cancer mainly occur, followed by liver cancer and colon cancer
.
Compared with the general population, the SIRs of SLE patients for overall, solid malignancies and hematological malignancies are 1.
8, 1.
7 and 5.
9, respectively
.
Among solid malignancies, head and neck, bladder, liver, pancreas, lung cancer, colon cancer, thyroid cancer, and breast and reproductive system are at increased risk in SLE patients
.
Female patients with SLE have a significantly increased risk of multiple myeloma, NHL, and solid cancers (such as breast or reproductive system, thyroid, liver, colon, lung, pancreatic, and bladder cancer), while male patients exhibit NHL The risk increases
.

This study included 17,854 SLE patients.
During the observation period (60,511 person-years [PYs]), 768 solid malignancies (126.
9 / 10,000 PYs) and 68 hematological malignancies (11.
2 / 10,000 PYs)
.
In SLE patients, breast cancer, reproductive system cancer and thyroid cancer mainly occur, followed by liver cancer and colon cancer
.
Compared with the general population, the SIRs of SLE patients for overall, solid malignancies and hematological malignancies are 1.
8, 1.
7 and 5.
9, respectively
.
Among solid malignancies, head and neck, bladder, liver, pancreas, lung cancer, colon cancer, thyroid cancer, and breast and reproductive system are at increased risk in SLE patients
.
Female patients with SLE have a significantly increased risk of multiple myeloma, NHL, and solid cancers (such as breast or reproductive system, thyroid, liver, colon, lung, pancreatic, and bladder cancer), while male patients exhibit NHL The risk increases
.

 

Original source:

Han et al.
Increased risk of malignancy in patients with systemic lupus erythematosus: population-based cohort study in Korea.
Arthritis Res Ther (2021) 23:270
https://doi.
org/10.
1186/s13075-021-02648-y

 

Leave a message here